{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T06:17:05Z","timestamp":1774678625853,"version":"3.50.1"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.jpba.2019.112846","type":"journal-article","created":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T02:04:04Z","timestamp":1567044244000},"page":"112846","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Development of a highly efficient decontamination approach for ceftolozane in the pharmaceutical manufacturing environment"],"prefix":"10.1016","volume":"177","author":[{"given":"Rong-Sheng","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Kang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roy","family":"Helmy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Andreani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhijian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huaming","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2019.112846_bib0005","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00253-003-1274-y","article-title":"Industrial production of beta-lactam antibiotics","volume":"61","author":"Elander","year":"2003","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"10.1016\/j.jpba.2019.112846_bib0010","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1001\/jama.2018.19283","article-title":"Evaluation and management of penicillin allergy: a review","volume":"321","author":"Shenoy","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.jpba.2019.112846_bib0015","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/ALN.0000000000002252","article-title":"Presumed \u03b2-Lactam allergy and cross-reactivity in the operating theater: a practical approach","volume":"129","author":"Hermanides","year":"2018","journal-title":"Anesthesiology"},{"key":"10.1016\/j.jpba.2019.112846_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2019.05.038","article-title":"Cross-reactivity to cephalosporins and carbapenems in penicillin-allergic patients: two systematic reviews and meta-analyses","author":"Picard","year":"2019","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"10.1016\/j.jpba.2019.112846_bib0025","doi-asserted-by":"crossref","first-page":"37","DOI":"10.18773\/austprescr.2018.008","article-title":"\u2018Cephalosporin allergy\u2019 label is misleading","volume":"41","author":"Yuson","year":"2018","journal-title":"Aust. Prescr."},{"key":"10.1016\/j.jpba.2019.112846_bib0030","first-page":"312","article-title":"ICH Q7A; 4.40 containment of beta-lactam antibiotics: an industry perspective","volume":"56","author":"Kasai","year":"2002","journal-title":"PDA J. Pharm. Sci. Technol."},{"key":"10.1016\/j.jpba.2019.112846_bib0035","series-title":"Guidance for Industry: Non-Penicillin Beta-Lactam Drugs: a CGMP Framework for Preventing Cross- Contamination","author":"US FDA","year":"2013"},{"key":"10.1016\/j.jpba.2019.112846_bib0040","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/j.scitotenv.2018.09.248","article-title":"Photolysis of four \u03b2\u2011lactam antibiotics under simulated environmental conditions: degradation, transformation products and antibacterial activity","volume":"651","author":"Timm","year":"2019","journal-title":"Sci. Total Environ."},{"key":"10.1016\/j.jpba.2019.112846_bib0045","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jhazmat.2014.07.008","article-title":"Degradation kinetics and mechanism of \u03b2-lactam antibiotics by the activation of H2O2 and Na2S2O8 under UV-254nm irradiation","volume":"279","author":"He","year":"2014","journal-title":"J. Hazard. Mater."},{"key":"10.1016\/j.jpba.2019.112846_bib0050","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/ejtc.34","article-title":"Alkaline and acidic hydrolysis of the \u03b2-lactam ring","volume":"2","author":"Frau","year":"1997","journal-title":"Electron. J. Theor. Chem."},{"key":"10.1016\/j.jpba.2019.112846_bib0055","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.scitotenv.2013.06.027","article-title":"pH and temperature effects on the hydrolysis of three \u03b2-lactam antibiotics: ampicillin, cefalotin and cefoxitin","volume":"466\u2013467","author":"Mitchell","year":"2014","journal-title":"Sci. Total Environ."},{"key":"10.1016\/j.jpba.2019.112846_bib0060","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.watres.2017.12.048","article-title":"Base-catalyzed hydrolysis and speciation-dependent photolysis of two cephalosporin antibiotics, ceftiofur and cefapirin","volume":"134","author":"Ribeiro","year":"2018","journal-title":"Water Res."},{"key":"10.1016\/j.jpba.2019.112846_bib0065","first-page":"399","article-title":"Hydroxylamine inactivation of cephalosporins: nucleophilic attack on beta-lactam structures","volume":"31","author":"Uri","year":"1984","journal-title":"Acta Microbiol. Hung"},{"key":"10.1016\/j.jpba.2019.112846_bib0070","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1002\/jps.2600651104","article-title":"Comparative stability of cephalosporins in aqueous solution: kinetics and mechanisms of degradation","volume":"65","author":"Yamana","year":"1976","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jpba.2019.112846_bib0075","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1021\/acs.oprd.7b00033","article-title":"Patent review of manufacturing routes to fifth-generation cephalosporin drugs. Part 1, ceftolozane","volume":"21","author":"Hughes","year":"2017","journal-title":"Org. Process Res. Dev."},{"key":"10.1016\/j.jpba.2019.112846_bib0080","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1517\/13543784.2014.930127","article-title":"Cephalosporins currently in early clinical trials for the treatment of bacterial infections","volume":"23","author":"Long","year":"2014","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.jpba.2019.112846_bib0085","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1128\/AAC.01590-12","article-title":"In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum \u03b2-lactamases, in the thighs of neutropenic mice","volume":"75","author":"Craig","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jpba.2019.112846_bib0090","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1016\/j.bmc.2007.11.074","article-title":"Structural requirements for the stability of novel cephalosporins to AmpC beta-lactamase based on 3D-structure","volume":"16","author":"Murano","year":"2008","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.jpba.2019.112846_bib0095","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1248\/cpb.54.1340","article-title":"An approach for decontamination of beta-lactam antibiotic residues or contaminants in the pharmaceutical manufacturing environment","volume":"54","author":"Fukutsu","year":"2006","journal-title":"Chem. Pharm. Bull."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708519316772?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708519316772?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T08:58:06Z","timestamp":1760000286000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708519316772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":19,"alternative-id":["S0731708519316772"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2019.112846","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of a highly efficient decontamination approach for ceftolozane in the pharmaceutical manufacturing environment","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2019.112846","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"112846"}}